Name: LIPOCINE INC (LPCN) Stock
Brand: LIPOCINE INC
Rating: 6 (3 reviews)

LPCN Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Lipocine Inc.

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025

3 months ago - By: Lipocine Inc.

Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference

3 months ago - By: Lipocine Inc.

Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025

6 months ago - By: Lipocine Inc.

Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada

7 months ago - By: Lipocine Inc.

Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology

7 months ago - By: Benzinga - Mentions: PTIX BCLI HCTI FBRX ...

12 Health Care Stocks Moving In Monday's Pre-Market Session

10 months ago - By: Lipocine Inc.

Lipocine Receives Updated Regulatory Guidance on LPCN 1154

a year ago - By: BusinessInsider

LPCN Stock Earnings: Lipocine Beats EPS, Misses Revenue for Q2 2024

2 years ago - By: InvestorPlace

LPCN Stock Earnings: Lipocine Beats EPS for Q1 2024

7 months ago - By: Lipocine Inc.

Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase

7 months ago - By: Benzinga - Mentions: AGEN RGC OMER WORX ...

12 Health Care Stocks Moving In Monday's Intraday Session

7 months ago - By: Lipocine Inc.

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025

a year ago - By: Lipocine Inc.

Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session

a year ago - By: Lipocine Inc.

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024

2 years ago - By: BusinessInsider

LPCN Stock Earnings: Lipocine Beats EPS for Q4 2023

2 years ago - By: InvestorPlace

LPCN Stock Earnings: Lipocine Beats EPS for Q4 2023

2 years ago - By: Lipocine Inc.

Lipocine to Present at 36th Annual Roth Conference

a year ago - By: Lipocine Inc.

Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®

a year ago - By: Lipocine Inc.

Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference

a year ago - By: InvestorPlace

LPCN Stock Earnings: Lipocine Beats EPS, Misses Revenue for Q2 2024

a year ago - By: Lipocine Inc.

Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study

1 years ago - By: Lipocine Inc.

Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024

2 years ago - By: Lipocine Inc.

Lipocine to Present at Biotech Showcase 2024

2 years ago - By: InvestorPlace - Mentions: FGEN NVCT RLMD ANIX ...

7 Penny Biotech Stocks to Triple Your Investment

2 years ago - By: Lipocine Inc.

Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024

2 years ago - By: Lipocine Inc.

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154

2 years ago - By: Lipocine Inc.

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

2 years ago - By: Lipocine Inc.

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154

2 years ago - By: Lipocine Inc.

Lipocine Announces Financial Results for the Full Year Ended December 31, 2023

2 years ago - By: Lipocine Inc.

Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals

2 years ago - By: InvestorPlace - Mentions: ELAB KPRX FBLG GMM ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

2 years ago - By: Seeking Alpha - Mentions: HALO

Lipocine licenses Tlando testosterone therapy to Verity Pharma (NASDAQ:LPCN)

2 years ago - By: Lipocine Inc.

Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada

2 years ago - By: Seeking Alpha

Lipocine files for $150M mixed shelf (NASDAQ:LPCN)

2 years ago - By: Lipocine Inc.

LIPOCINE INC (LPCN) Stock News

LPCN Latest News, Press Relases and Analysis

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025

Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference

Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025

Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada

Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology

12 Health Care Stocks Moving In Monday's Pre-Market Session

Lipocine Receives Updated Regulatory Guidance on LPCN 1154

LPCN Stock Earnings: Lipocine Beats EPS, Misses Revenue for Q2 2024

LPCN Stock Earnings: Lipocine Beats EPS for Q1 2024

Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase

12 Health Care Stocks Moving In Monday's Intraday Session

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025

Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024

LPCN Stock Earnings: Lipocine Beats EPS for Q4 2023

LPCN Stock Earnings: Lipocine Beats EPS for Q4 2023

Lipocine to Present at 36th Annual Roth Conference

Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®

Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference

LPCN Stock Earnings: Lipocine Beats EPS, Misses Revenue for Q2 2024

Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study

Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024

Lipocine to Present at Biotech Showcase 2024

7 Penny Biotech Stocks to Triple Your Investment

Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154

Lipocine Announces Financial Results for the Full Year Ended December 31, 2023

Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Lipocine licenses Tlando testosterone therapy to Verity Pharma (NASDAQ:LPCN)

Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada

Lipocine files for $150M mixed shelf (NASDAQ:LPCN)

Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023